Ocular Therapeutix, Inc. (OCUL)

NGM – Real Time Price. Currency in USD

10.24

+0.48 (4.92%)

Market open: Aug 12, 2026, 1:53 PM EDT

9.80

+0.04 (0.41%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

07.08.2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees.

05.08.2026

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Ocular Therapeutix (OCUL) is positioned for a potential 2027 launch of AXPAXLI, with a de-risked regulatory path and strong Phase 3 efficacy data. AXPAXLI's annual dosing and clinic productivity benefits could drive adoption beyond wet AMD, targeting broader retinal indications including diabetic retinopathy. The FDA has agreed to an NDA submission in Q4 2026 based on SOL-1 data and interim safety from SOL-R, reducing near-term regulatory risk.

03.08.2026

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago.

03.08.2026

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026

Videos

No Data

There is no data to display

Press releases

07.08.2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03.08.2026

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026

Ocular Therapeutix, Inc. (OCUL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Videos

No Data

Press releases

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Videos

No Data

Press releases

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Search stocks

Ocular Therapeutix, Inc. (OCUL)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Videos

No Data

Press releases

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Videos

No Data

Press releases

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights